EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Non‐Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer

S A Hamza, R Paolini, N M O'Brien-Simpson, W Singleton, R Patini, M McCullough, A Celentano iD

Oral Diseases · 2025-06 · 31 (6) · 1672-1683

DOI: 10.1111/odi.15288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 03.03.2025. Verfasst von S A Hamza und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Dentistry and Health Sciences, Melbourne Dental School, Carlton, Victoria, Australia. Hauptthemen laut MEDLINE: Heparin, Mouth Neoplasms, Carcinoma, Squamous Cell, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Melbourne.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oral squamous cell carcinoma (OSCC) represents a significant global oral health concern. Non‐anticoagulant heparin (NH) emerges as a promising solution considering the enhanced survival observed with anticoagulants in cancer treatment.

Methods

We used the MTS assay (0/24/48/72 h), scratch assay (MuviCyte, 0–18 h), invasion Matrigel (24 h), and cytotoxic assay (0–24 h) to assess the in vitro effects of NH and heparin (10, 20, 40, 80 U/mL) on three oral human cell lines (H400/H357/OKF6) as well as their ability to interfere with the chemotherapeutic agents 5FU and cisplatin (1–5 μg/mL).

Results

Remarkably, NH not only significantly induced a significant cytotoxic effect on both cancer cell lines at 80 U/mL but also inhibited proliferation at 48/72 h to a comparable extent as heparin. Notably, neither drug exhibited cytotoxic effects on the normal cells. Furthermore, in H400/H357 cells, both heparin and NH significantly inhibit the cell migration and invasion rate. Importantly, the combination of these drugs with commonly used chemotherapeutic agents for OSCC treatment did not compromise their efficacy against the tested cell lines.

Conclusion

NH demonstrates promising potential without compromising the efficacy of commonly used chemotherapeutic agents. These results underscore the need for the translation of this research to preclinical animal models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HeparinMouth NeoplasmsCarcinoma, Squamous CellAntineoplastic AgentsHumansCell Line, TumorCell ProliferationCell MovementCisplatinFluorouracilNeoplasm InvasivenessAnticoagulants

Stichwörter der Autor:innen

OSCCchemotherapeutic agentsheparinnon‐anticoagulant heparinoral cancer

Substanzen

HeparinCisplatinAntineoplastic AgentsFluorouracilAnticoagulants

Autor:innen und Institutionen

  • Faculty of Medicine, Dentistry and Health Sciences, Melbourne Dental School, Carlton, Victoria, Australia.
  • Head and Neck Department, "Fondazione Policlinico Universitario A. Gemelli - IRCCS" School of Dentistry, Catholic University of Sacred Heart - Rome, Rome, Italy.

ORCID-Profile: A Celentano

Förderung

  • University of Melbourne

Zitieren

APA

Hamza, S. A., Paolini, R., O'Brien-Simpson, N. M., Singleton, W., Patini, R., McCullough, M., & Celentano, A. (2025). Non‐Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer. Oral Diseases, 31(6), 1672-1683. https://doi.org/10.1111/odi.15288

Vancouver

Hamza SA, Paolini R, O'Brien-Simpson NM, Singleton W, Patini R, McCullough M, et al. Non‐Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer. Oral Diseases. 2025;31(6):1672-1683. doi:10.1111/odi.15288

BibTeX
@article{Hamza2025,
  author = {Hamza, S A and Paolini, R and O'Brien-Simpson, N M and Singleton, W and Patini, R and McCullough, M and Celentano, A},
  title = {Non‐Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer},
  journal = {Oral Diseases},
  year = {2025},
  volume = {31},
  number = {6},
  pages = {1672--1683},
  doi = {10.1111/odi.15288}
}
Kostenlos starten →